Isolation, immortalization and characterization of human B lymphocytes for the development of diagnostic and therapeutic antibodies against cancer.
Recruiting
- Conditions
- anti-cancer antibodies / cancer eradication100243241001799010040900
- Registration Number
- NL-OMON47403
- Lead Sponsor
- AIMM Therapeutics BV
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 75
Inclusion Criteria
o patients with a hematologic malignancy (leukemia or lymphoma) who received a hematopoetic stem cell transplantation and subsequently developed graft-versus-host disease and/or a sustained graft-versus-leukemia response;
o patients with melanoma who showed spontaneous or treatment induced tumor regression, preferably in the presence of signs of auto-immunity , like vitiligo;
o patients with gastrointestinal tumors (pancreatic or oesophagus) with either tumor regression or slower then expected tumor growth.
Exclusion Criteria
no
Study & Design
- Study Type
- Observational invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>The identification and production of tumor-specific monoclonal antibodies by<br /><br>the generation of tumor specific B lymphocyte clones.</p><br>
- Secondary Outcome Measures
Name Time Method <p>not applicable</p><br>